Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.

Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E, Bruckers L, Droogne W, Troisfontaines P, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M.

Eur J Heart Fail. 2018 Nov;20(11):1591-1600. doi: 10.1002/ejhf.1307. Epub 2018 Sep 21.


Long-term impact of a six-month telemedical care programme on mortality, heart failure readmissions and healthcare costs in patients with chronic heart failure.

Frederix I, Vanderlinden L, Verboven AS, Welten M, Wouters D, De Keulenaer G, Ector B, Elegeert I, Troisfontaines P, Weytjens C, Mullens W, Dendale P.

J Telemed Telecare. 2019 Jun;25(5):286-293. doi: 10.1177/1357633X18774632. Epub 2018 May 10.


Effect of a telemonitoring-facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: the TEMA-HF 1 (TElemonitoring in the MAnagement of Heart Failure) study.

Dendale P, De Keulenaer G, Troisfontaines P, Weytjens C, Mullens W, Elegeert I, Ector B, Houbrechts M, Willekens K, Hansen D.

Eur J Heart Fail. 2012 Mar;14(3):333-40. doi: 10.1093/eurjhf/hfr144. Epub 2011 Nov 1.


Eco-, geno- and human toxicology of bio-active nanoparticles for biomedical applications.

Robbens J, Vanparys C, Nobels I, Blust R, Van Hoecke K, Janssen C, De Schamphelaere K, Roland K, Blanchard G, Silvestre F, Gillardin V, Kestemont P, Anthonissen R, Toussaint O, Vankoningsloo S, Saout C, Alfaro-Moreno E, Hoet P, Gonzalez L, Dubruel P, Troisfontaines P.

Toxicology. 2010 Mar 10;269(2-3):170-81. doi: 10.1016/j.tox.2009.11.002. Epub 2009 Nov 26.


Type III secretion: more systems than you think.

Troisfontaines P, Cornelis GR.

Physiology (Bethesda). 2005 Oct;20:326-39. Review.


[Clinical case of the month. Precordialgia evoking a coronary instability syndrome, a diagnostic danger].

Gach O, Troisfontaines P, Legrand V.

Rev Med Liege. 2003 Oct;58(10):611-4. French.


Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction.

Lancellotti P, Troisfontaines P, Toussaint AC, Pierard LA.

Circulation. 2003 Oct 7;108(14):1713-7. Epub 2003 Sep 15.


[Image of the month. Isolated single coronary artery or blockage of the common arterial trunk and branches? ].

Gach O, Troisfontaines P, Legrand V.

Rev Med Liege. 2003 Mar;58(3):117-8. French. No abstract available.


Identification of substrates and chaperone from the Yersinia enterocolitica 1B Ysa type III secretion system.

Foultier B, Troisfontaines P, Vertommen D, Marenne MN, Rider M, Parsot C, Cornelis GR.

Infect Immun. 2003 Jan;71(1):242-53.


Characterization of the ysa pathogenicity locus in the chromosome of Yersinia enterocolitica and phylogeny analysis of type III secretion systems.

Foultier B, Troisfontaines P, Müller S, Opperdoes FR, Cornelis GR.

J Mol Evol. 2002 Jul;55(1):37-51.


Effect of low- and high-virulence Yersinia enterocolitica strains on the inflammatory response of human umbilical vein endothelial cells.

Denecker G, Tötemeyer S, Mota LJ, Troisfontaines P, Lambermont I, Youta C, Stainier I, Ackermann M, Cornelis GR.

Infect Immun. 2002 Jul;70(7):3510-20.

Supplemental Content

Loading ...
Support Center